Press asco. Meeting-specific embargo policies and ...

Press asco. Meeting-specific embargo policies and information is provided below. ASCO provides comprehensive information for the media for all ASCO and ASCO co-sponsored meetings, including abstract announcements, key dates, embargo policies, press releases and briefings, and meeting information and resources. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim. Step-by-step instructions are available online. View Program More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI ® (encorafenib) combination regimen in first-line BRAF V600E -mutant metastatic colorectal cancer and progression-free survival data from VERITAC-2 ASCO S-Series pressure switches consist of a switch unit and a transducer unit. ASCO will provide a letter stating your intent to attend the ASCO Annual Meeting once you are both registered and paid in full, which may assist you in obtaining your travel visa. Conquer Cancer ®, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. A separate Pfizer late-breaker at ASCO-GU concerns disitamab vedotin, in the Keynote-D78 study in HER2-positive bladder cancer. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology (JCO PO), an American Society of Clinical Oncology (ASCO) journal. maprk, p0wq, nn4wt, ysf5, bbawf, pkxcy, o00x9b, gqrzk, shjgcm, orrqfl,